View Press Releases
-
Innovation and automation are driving forces behind next generation cell therapy manufacturing platform from Cytiva
-
ZeOmega Names Tabatha Fuchs Chief Marketing and Communications Officer
-
Sakura Finetek Europe B.V. advances its laboratory automation with the Tissue-Tek xPrint® LP Laser Cassette Printer
Sakura Finetek Europe announces the launch of its newest advancement in tissue sample identification bringing laboratory workflows to the next level.
May 28, 2024
-
Indica Labs Announces AI-Powered HALO® Software Release for Digital Pathology Research in Life Sciences
Indica Labs announced today the release of the transformative new version of its industry leading life sciences software.
May 28, 2024
-
ResultsCX Achieves Coveted Great Place to Work® Certification™ Across Five Countries
-
SPT Labtech’s firefly® liquid handler chosen by Colossal Biosciences to accelerate NGS capabilities in fight against species extinction and biodiversity loss
-
Creative Enzymes Introduces Leaf-branch Compost Poly (ethylene terephthalate) Hydrolase for Sustainable PET Degradation
-
Study Demonstrates MyPhenome Hungry Gut Test Identifies Responders to Semaglutide
New independent study’s findings presented during Presidential Plenary session at Digestive Disease Week 2024.
May 27, 2024
-
Integrated DNA Technologies Invests in New U.S. Synthetic Biology Manufacturing Facility
-
Creative Enzymes Introduces Recombinant Porcine Citrate Synthase with Enhanced C-His Tag for Accelerated Metabolic Research
-
SPT Labtech and Watchmaker Genomics Partner to Simplify and Streamline NGS Library Preparation
-
Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395
Today, Owkin has unveiled its precision AI drug pipeline in oncology & immunology. To accelerate time-to-patient impact, Owkin has in-licensed OKN4395, a highly selective and potent EP2/4 dual antagonist from Idorsia that will enter Phase 1 trials in early 2025.
May 22, 2024
-
Unraveling the Mysteries of Protein Lipidation with Creative Proteomics
-
PathAI and Aster Insights Partner to Deliver Combined AI-Derived Structured Pathology and Multimodal Real-World Data Solutions
PathAI, a global leader in AI-powered pathology, and Aster Insights, the leading provider of scientific and clinical intelligence for oncology discovery, today announced a multi-year strategic partnership to develop curated multimodal datasets that pair PathAI’s PathExplore1 artificial intelligence (AI) tumor microenvironment (TME) quantification panel with Aster Insights’ Avatar clinical, molecular, and digital pathology imaging data. By combining their respective best-in-class platforms, PathAI and Aster Insights will be able to expedite the development of novel insights to accelerate the discovery and development of new treatments for patients with cancer.
May 22, 2024
-
Record numbers expected at CPHI & PMEC China 2024 as Asian markets boom
Domestic and international markets in Asia surging as CPHI & PMEC China welcomes 60,000 attendees and 3500 exhibitors
May 22, 2024
-
Qlucore releases unique AI-based solution in the field of lung cancer subtyping
Qlucore, listed on Nasdaq First North, can now release a new version of Qlucore Insights specifically designed for the lung cancer field, with the capability to classify primary lung samples as well as metastatic lesions. The lung cancer model is being developed with Heidelberg University Hospital, supported by a Eurostars Joint European Programme grant.
May 22, 2024
-
Vaxess Announces $12M in Funding
-
Protheragen-ING Lab, a Trustworthy GLP Service Provider, Unveils Its Cutting-Edge Medical Device Services
-
CD Formulation Provides Genotoxic Impurity Testing Services to Detect and Evaluate the Potential of GIs for API and Drug Substances
-
Cresset appoints new Non-Executive Director